Monograph Capital Partners β Full Portfolio
24 tracked investments Β· listed companies and verified rows first
A US-headquartered biotech company developing innovative solutions for urothelial and specialty cancers using RTGel hydrogel technology (exited July 2025).
BiotechPrinceton, US
Stuart Holden, M.D.(Director)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Fred Cohen, M.D.(Director)Don Kim(Executive Officer)
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MEREDITH FISHER(Director)MICHAEL LIPP(Executive Officer)
Board seatFreddie DearΒ· per SEC Form D
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
Austin, US
Board seatTravis MurdochΒ· per SEC Form D
A gene-to-GMP contract development and manufacturing organization for advanced modalities and gene therapies.
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
A clinical-stage biotechnology company developing adjunctive therapies for depressive illnesses and bipolar depression.
Autobahn develops medicines for central nervous system (CNS) disorders by leveraging regenerative mechanisms of the human body.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)
BoardKristina Burow(Director)Thomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)
A precision immunology company co-incubated with Arch Venture Partners leveraging human genetics for autoimmune disorder treatments (exited May 2024).
A UK-based preclinical biotechnology company developing antibody drugs against ion channels and GPCRs using proprietary KnotBody technology.
A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).
Ouro Medicines is a company based in South San Francisco, California.
BiotechSouth San Francisco, US
A US-based biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases using half-life extension technology.
A clinical-stage neuro-immunology company advancing TYK2 inhibitors for multiple sclerosis and psoriasis.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.